BioCytics Taps Eremid Genomics to Sequence Cancer Cell Therapy
Image
Huntersville, N.C. – September 20, 2026 -- BioCytics, Inc. has engaged Eremid Genomic Services to perform single cell transcriptomic and TCR sequencing analysis on immune cells central to its autologous cancer cell therapy program.
Eremid will characterize immune precursor cells before clinical deployment
The North Carolina-based genomics contract research organization will run scRNA-Seq and TCR sequencing on an autologous immune cell fraction supplied by BioCytics. The analysis is designed to confirm whether expanded immune cells are biologically fit for cancer-killing activity and to map their mechanism of action ahead of reinfusion into patients.